KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EPS (Basic) (2018 - 2025)

Amneal Pharmaceuticals (AMRX) has 8 years of EPS (Basic) data on record, last reported at $0.11 in Q4 2025.

  • For Q4 2025, EPS (Basic) rose 210.0% year-over-year to $0.11; the TTM value through Dec 2025 reached $0.23, up 160.53%, while the annual FY2025 figure was $0.23, 160.53% up from the prior year.
  • EPS (Basic) reached $0.11 in Q4 2025 per AMRX's latest filing, up from $0.01 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.11 in Q4 2025 and bottomed at -$0.8 in Q2 2022.
  • Average EPS (Basic) over 5 years is -$0.07, with a median of $0.0 recorded in 2022.
  • The widest YoY moves for EPS (Basic): up 400.0% in 2023, down 1833.33% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$0.05 in 2021, then skyrocketed by 40.0% to -$0.03 in 2022, then crashed by 1833.33% to -$0.58 in 2023, then soared by 82.76% to -$0.1 in 2024, then skyrocketed by 210.0% to $0.11 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were $0.11 in Q4 2025, $0.01 in Q3 2025, and $0.07 in Q2 2025.